Kivu Bioscience is naming Brunilda Shtylla Chief Business Officer, with Shtylla assuming the same role she held at Sutro Biopharma. Shtylla is tasked with leading corporate strategy, business development, and partnership initiatives as Kivu advances its antibody-drug conjugate (ADC) pipeline. As a clinical-stage biotechnology company, Kivu develops next-generation ADCs for difficult-to-treat cancers. How Shtylla Will Impact Kivu Shtylla’s appointment signals the company’s desire to adva...